DeepSight™ Technology Receives First FDA 510(k) Clearance for NeedleVue™ LC1 Ultrasound System
SANTA CLARA, Calif., Aug. 13, 2025 /PRNewswire/ — DeepSight Technology, a medical imaging pioneer, announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its NeedleVue™ LC1 Ultrasound System.
This clearance marks an important step forward in DeepSight's development of its NeedleVue™ and OnPoint™ technologies that will work in tandem with the NeedleVue™ LC1 Ultrasound System to transform image-guided procedures. 'This is a foundational milestone in our mission to deliver crystal clear, sub millimeter level guidance inside the body,' said Nader Sadrzadeh CEO of DeepSight. 'We have developed the next generation sensor technology for enhancing ultrasound where it what matters most—clear visualization, procedural efficiency, and user confidence. We're just getting started and look forward to building on this achievement as we expand our clinical and commercial momentum in the months ahead.'
To learn more about the NeedleVue™ LC1 Ultrasound System and DeepSight's mission to advance procedural ultrasound, visit www.deepsight.com.
Visit DeepSight at the upcoming LSI'25 Europe meeting in London September 7th – 11th and Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference in Barcelona, September 13–17, to experience NeedleVue technology firsthand.
About DeepSight TechnologyDeepSight Technology, founded in 2019 by Nader Sadrzadeh, Lan Yang, and Anand Chandrasekher, is built on a bold vision — to revolutionize medical imaging through proprietary sensing technology. With offices in the San Francisco Bay Area and Clayton, Missouri, DeepSight aims to extend the capabilities of ultrasound across diagnostic, therapeutic, surgical, and interventional applications —advancing patient care and improving public health worldwide. Our next-generation sensor technology will transform ultrasound, with the goal to deliver exceptional clarity, pinpoint precision, and unparalleled confidence for clinicians in every procedure.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Children's Hospital of Philadelphia and Children's Hospital Colorado Researchers Conduct First Prospective Study of Pediatric EoE Patients and Disease Progression
Study found that stiffness of the esophagus could serve as an important biomarker for disease progression and indicate which patients may benefit the most from current therapies PHILADELPHIA, Aug. 15, 2025 /PRNewswire/ — Researchers from Children's Hospital of Philadelphia (CHOP) and Children's Hospital Colorado have found that better control of chronic eosinophilic esophagitis (EoE)-associated inflammation during childhood leads to less stiffening of the esophagus, resulting in fewer disease complications. Using Endoluminal functional imaging (FLIP), the study team suggests this could be a key marker for assessing disease severity and progression. The findings were published online today by the journal Gastroenterology. EoE is a chronic allergic inflammatory disease of the esophagus, the muscular tube that carries food from the throat to the stomach. Children can experience nausea, regurgitation, vomiting, abdominal pain and a burning feeling like acid reflux. They may also have difficulty swallowing and gag frequently. Often, they can experience dysphagia, which is when it feels like something is stuck in their throat. If EoE goes untreated, the esophagus may narrow because of scarring, a phenomenon known as stricture. Chronic EoE-associated inflammation can lead to progressive tissue remodeling and fibrostenosis, or the narrowing of the esophagus. While clinicians recognize the severity of the disease, long-term studies looking at disease progression over time, and the impact of controlling the disease from a young age, is relatively unknown. 'This is the first study to follow kids overtime (with these endoscopic assessments) and evaluate the patients who are at the highest risk of complications,' said co-senior study author Amanda Muir, MD, a pediatric gastroenterologist in the Division of Gastroenterology, Hepatology and Nutrition at CHOP. 'With the recent FDA approval of two medications for EoE, having this data could help identify the patients who could benefit from these therapies the most and observe improvement at a histologic level over time.' Researchers at CHOP and Children's Hospital Colorado launched a longitudinal study to evaluate long-term changes in esophageal distensibility, or the ability of the esophagus to expand, in pediatric patients between the ages of 3 and 18 years old. Symptomatic, endoscopic and histologic data were collected at each visit during the study. A total of 112 patients with EoE were included with a median follow-up time of 11 months, some followed for over 4 years. 'Following children living with EoE over time has given us a clearer picture of how inflammation affects the esophagus and how treating it can improve the esophagus and outcomes for patients,' said Calies Menard-Katcher, MD, co-senior study author and Associate Director of Clinical Research for the Gastrointestinal Eosinophilic Diseases Program at Children's Hospital Colorado. 'It's exciting to see these results confirm what we've suspected in caring for patients — and they may even help us spot those at risk for more severe disease.' The study found that patients with tissue samples showing a response to treatment demonstrated the most improvement in distensibility over time. After adjusting for different factors, the study found that patients with lower esophageal distensibility had increased odds of patient-reported dysphagia, or difficulty swallowing. Patients with fibrostenosis were generally diagnosed at an older age, had the disease for a longer period and showed reduced esophageal distensibility at baseline predicted the need for future dilation in patients with strictures. The authors suggest that further studies that examine the disease from a molecular level could help them understand which patients may be at highest risk of severe disease and could benefit from a variety of treatment strategies. This study was supported by the National Institutes of Health grants R01DK124266-01, K23DK109263 and R21TR003039. Kennedy et al, 'Histologic response is associated with improved esophageal distensibility and symptom burden in pediatric eosinophilic esophagitis.' Gastroenterology. Online August 15, 2025. DOI: 10.1053/ About Children's Hospital of Philadelphia:A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center) and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit ABOUT CHILDREN'S HOSPITAL COLORADO Children's Hospital Colorado is one of the nation's leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and ranked among the best children's hospitals in the nation as recognized by U.S. News & World Report, Children's Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children's Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region. For more information, visit or connect with us on Facebook, Instagram and YouTube. Contact: Ben LeachChildren's Hospital of Philadelphia(609)634-7906leachb@
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Keystone Custom Homes Breaks Ground in South Carolina
CHARLOTTE, N.C, Aug. 15, 2025 /PRNewswire/ — Keystone Custom Homes is excited to announce its expansion into South Carolina, with the groundbreaking of Arbor Gate, a new community just outside of Greenville. This milestone marks the company's presence in four states across the Mid-Atlantic and Southeast. 'The entire Keystone team is honored to have our first opportunity in South Carolina being in the desirable Five Forks area of Greenville. We look forward to matching our great home plans with home buyers' ideas to build dream homes!' said Alan Banks, CEO of the Carolinas Division at Keystone Custom Homes. About Arbor Gate Located in the sought-after Five Forks area, Arbor Gate will feature 57 custom-built homes. At the heart of the community, a 6-acre park will offer walking trails, a fire pit, beautiful landscaping, and inviting gathering spaces for friends and family. With easy access to I-85 and I-385, residents can enjoy a quick commute to the city along with an abundance of nearby dining, shopping, and entertainment options. Tree-lined streets will create a peaceful, private setting while offering picturesque views. For more details, visit the Arbor Gate community page on the Keystone Custom Homes website. Upcoming Launch: The Gables at Handsmill On August 25rd, Keystone Custom Homes will debut The Gables at Handsmill in York, SC —an exclusive opportunity featuring waterfront homesites and stunning floorplans within an established community. Residents will enjoy access to a community clubhouse with a fitness center, social lounge, catering kitchen, and pool, as well as a splash pad and playground for children. Interested buyers can join the VIP list by visiting the Coming Soon page on their website. About Keystone Custom Homes Keystone Custom Homes builds award-winning custom homes across Pennsylvania, Maryland, North Carolina, and South Carolina, offering buyers the opportunity to build a home that is tailored to their lifestyle and budget. From selecting a floorplan to customizing every detail, Keystone's expert team guides buyers through every step of the process. They are dedicated to bringing dream homes to life. In 2019, founder and CEO Jeff Rutt demonstrated the company's commitment to giving back by donating 90% of Keystone's ownership to the National Christian Foundation. Through their partnership with HOPE International, Keystone supports micro-loans for underprivileged individuals globally, empowering them to start businesses and provide for their families. Together with their trade partners, expert team, and customers, Keystone Custom Homes strives to be Craftsmen for the Common Good in its communities throughout the Mid-Atlantic and Southeast.
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Deribit Introduces Linear Options for BTC and ETH
Launch reinforces Deribit's dedication to innovation and delivering premier trading solutions to market DUBAI, UAE, Aug. 15, 2025 /PRNewswire/ — Deribit, the world's premier digital assets derivatives exchange, today announced the launch of new linear options contracts for BTC and ETH, priced and settled in USDC, effective August 19. They come with new USDC-settled BTC & ETH dated futures, alongside the existing USDC-settled perpetual futures. The launch of these new platform features was driven by strong institutional and retail demand. This latest addition to the Deribit platform follows just over a year after the successful integration of linear options for altcoins, including SOL and XRP, also settled in USDC. It also comes on the heels of USDC rewards being introduced, enabling users to earn passive returns on USDC holdings without requiring staking, lockups, or any manual action. The positive reception and growing demand for stablecoin-settled options in the altcoin space demonstrated the market's readiness for more flexible and accessible derivatives products. Building on that momentum, Deribit is now expanding its linear options offering to include BTC and ETH. Deribit CEO Luuk Strijers commented on the news, 'The introduction of linear options for BTC and ETH marks a significant milestone in our mission to offer institutional-grade products tailored to the evolving needs of our clients. By settling in USDC, we're providing greater flexibility, capital efficiency, and a familiar fiat-equivalent structure that appeals to both institutional and retail participants.' Linear options are financial derivatives whose payouts move in direct proportion to the price of the underlying asset. As the asset's price rises or falls, the value of the option adjusts accordingly, offering traders a predictable and transparent exposure to market movements. These instruments are commonly utilized for purposes such as hedging, speculative positioning, and yield enhancement, making them a valuable addition to a comprehensive trading strategy. The introduction of linear options will have no impact on Deribit's existing inverse BTC and ETH options (priced and settled in BTC, ETH) which will continue to operate as usual. The new linear options are fully integrated into the platform's risk engine and will offset inverse options for margin purposes, providing greater capital efficiency for traders managing both product types. They also come in smaller minimum order sizes (0.01 BTC and 0.1 ETH only) than the existing inverse options to provide better accessibility. For additional information, visit: About DeribitDeribit is a centralized, institutional-grade crypto derivatives exchange for options and futures trading based in Dubai, United Arab Emirates. Deribit's state-of-the-art infrastructure offers instantaneous price discovery, low latency trading, advanced risk mitigation services, and deep liquidity via its network of top-tier market makers. Led by a team with decades of experience in options trading across all markets, Deribit facilitates a significant majority of all crypto options trading and has robust proof of assets and liabilities procedures to ensure the exchange is held to the highest of standards. Deribit is a subsidiary of Coinbase (NASDAQ: COIN), a publicly-traded cryptocurrency platform founded in 2012. Coinbase is on a mission to increase economic freedom for more than 1 billion people. For additional information, visit: Media Contact M Group Strategic Communications (On behalf of Deribit)deribitpr@
